Drug Trial Radar · NCT05989711
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
Last checked: Nov 19, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
212
Actual
Start
Jul 27, 2023
Primary completion
Nov 25, 2025
Study completion Nov 25, 2025
Sponsor
- Lead sponsor
- Altimmune, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
Conditions
- Non-Alcoholic Steatohepatitis (NASH)
Interventions
PemvidutideDrug
Administered once weekly by subcutaneous injection
PlaceboDrug
Administered once weekly by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosisTime frame: 24 weeks
- Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis)Time frame: 24 weeks
- Incidence of Treatment Emergent Adverse EventsTime frame: 52 weeks
Locations
40 sites in 3 countries. Site status is shown where the registry gives one.
Altimmune Clinical Study Site
Chandler, Arizona
Altimmune Clinical Study Site
Peoria, Arizona
Altimmune Clinical Study Site
Tucson, Arizona
Altimmune Clinial Study Site
Tucson, Arizona
Altimmune Clinical Study Site
North Hollywood, California
Altimmune Clinical Study Site
Panorama City, California
Altimmune Clinical Study Site
Englewood, Colorado
Altimmune Clinical Study Site
Bradenton, Florida
Altimmune Clinical Study Site
Fort Myers, Florida
Altimmune Clinical Study Site
Hialeah Gardens, Florida
Altimmune Clinical Study Site
Miami Lakes, Florida
Altimmune Clinical Study Site
Port Orange, Florida
Altimmune Clinical Study Site
Sarasota, Florida
Altimmune Clinical Study Site
West Palm Beach, Florida
Altimmune Clinical Study Site
Dalton, Georgia
Altimmune Clinical Study Site
Marietta, Georgia
Altimmune Clinical Study Site
Bastrop, Louisiana
Altimmune Clinical Study Site
Shreveport, Louisiana
Altimmune Clinical Study Site
Clarksville, Tennessee
Altimmune Clinical Study Site
Germantown, Tennessee
Altimmune Clinical Study Site
Austin, Texas
Altimmune Clinical Study Site
Bellaire, Texas
Altimmune Clinical Study Site
Edinburg, Texas
Altimmune Clinical Study Site
Edinburg, Texas
Altimmune Clinical Study Site
Georgetown, Texas
Altimmune Clinical Study Site
Houston, Texas
Altimmune Clinical Study Site
San Antonio, Texas
Altimmune Clinical Study Site
San Antonio, Texas
Altimmune Clinical Study Site
West Jordan, Utah
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Liverpool Hospital
Liverpool, New South Wales, Australia
Princess Alexandra Hospital/ Translational Research Institute
Woolloongabba, Queensland, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
St. Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia
Austin Health
Heidelberg, Victoria, Australia
Box Hill Hospital
Box Hill, Victory, Australia
Monash Hospital
Clayton, Victory, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
Altimmune Clinical Study Site
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.